Organon & Co | OGN - Ebitda


Organon & Co reported $383M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Celltrion KRW 374.56B 352.67B Sep/2025
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Deva Holding AS TRY 882.9M 201.7M Sep/2023
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 8.9B 20M Dec/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Kangmei Pharma CNY 17.3M 20.56M Jun/2025
Knight Therapeutics CAD 15.51M 3.39M Jun/2025
Laboratorios Farma EUR 34.94M 102.95M Jun/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Medical Developments International AUD 1.78M 3.78M Dec/2024
Merck USD 8.39B 1.97B Sep/2025
Neuren Pharmaceuticals AUD 176.7M 166.79M Dec/2024
Novartis USD 5.84B 235M Sep/2025
Organigram Holdings CAD 6.15M 455K Sep/2025
Organon & Co USD 383M 135M Dec/2025
Pharma Mar EUR -1.98M 28.13M Sep/2025
Qiagen NV USD 249.69M 56.53M Dec/2025
Sartorius EUR 277.4M 30.5M Dec/2025
Sino Biopharmaceutical CNY 2.59B 1.57B Dec/2024
Tilray USD 8.36M 1.82M Sep/2025